MA41421B1 - Anticorps humains contre la glycoprotéine du virus ebola - Google Patents
Anticorps humains contre la glycoprotéine du virus ebolaInfo
- Publication number
- MA41421B1 MA41421B1 MA41421A MA41421A MA41421B1 MA 41421 B1 MA41421 B1 MA 41421B1 MA 41421 A MA41421 A MA 41421A MA 41421 A MA41421 A MA 41421A MA 41421 B1 MA41421 B1 MA 41421B1
- Authority
- MA
- Morocco
- Prior art keywords
- ebola virus
- antibodies
- human antibodies
- virus glycoprotein
- bind
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La présente invention concerne des anticorps monoclonaux, ou des fragments de liaison à l'antigène de ceux-ci, qui se lient aux glycoprotéines du virus Ebola, des compositions pharmaceutiques comprenant les anticorps et des procédés d'utilisation. Les anticorps de l'invention peuvent servir à inhiber ou neutraliser l'activité du virus Ebola, offrant ainsi un moyen de traitement ou de prévention d'une infection par le virus Ebola chez l'homme. Dans certains modes de réalisation, l'invention concerne l'utilisation d'un ou de plusieurs anticorps qui se lient au virus Ebola pour empêcher la fixation virale et/ou l'entrée dans des cellules hôtes. Les anticorps de l'invention peuvent être utilisés de manière prophylactique ou thérapeutique et peuvent être utilisés seuls ou en combinaison avec un ou plusieurs autres vaccins ou agents antiviraux.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562107581P | 2015-01-26 | 2015-01-26 | |
| US201562161356P | 2015-05-14 | 2015-05-14 | |
| US201562245703P | 2015-10-23 | 2015-10-23 | |
| EP16703030.3A EP3250591B1 (fr) | 2015-01-26 | 2016-01-25 | Anticorps humains contre la glycoprotéine du virus ebola |
| PCT/US2016/014720 WO2016123019A1 (fr) | 2015-01-26 | 2016-01-25 | Anticorps humains contre la glycoprotéine du virus ebola |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA41421A MA41421A (fr) | 2017-12-05 |
| MA41421B1 true MA41421B1 (fr) | 2026-02-27 |
Family
ID=55300806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41421A MA41421B1 (fr) | 2015-01-26 | 2016-01-24 | Anticorps humains contre la glycoprotéine du virus ebola |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US9771414B2 (fr) |
| EP (2) | EP4653051A3 (fr) |
| JP (4) | JP6829199B2 (fr) |
| KR (1) | KR102641731B1 (fr) |
| CN (2) | CN107667115B (fr) |
| AU (2) | AU2016211783B2 (fr) |
| BR (1) | BR112017015845A2 (fr) |
| CA (1) | CA2974899A1 (fr) |
| CL (3) | CL2017001920A1 (fr) |
| CO (1) | CO2017007619A2 (fr) |
| DK (1) | DK3250591T3 (fr) |
| EA (1) | EA038993B1 (fr) |
| ES (1) | ES3054263T3 (fr) |
| FI (1) | FI3250591T3 (fr) |
| HR (1) | HRP20251642T1 (fr) |
| IL (1) | IL253358B (fr) |
| LT (1) | LT3250591T (fr) |
| MA (1) | MA41421B1 (fr) |
| MD (1) | MD3250591T2 (fr) |
| MX (2) | MX392533B (fr) |
| MY (4) | MY196224A (fr) |
| PH (1) | PH12017501277B1 (fr) |
| PL (1) | PL3250591T3 (fr) |
| PT (1) | PT3250591T (fr) |
| RS (1) | RS67563B1 (fr) |
| SG (2) | SG10202007835QA (fr) |
| SI (1) | SI3250591T1 (fr) |
| SM (1) | SMT202500454T1 (fr) |
| TW (1) | TWI710573B (fr) |
| UY (1) | UY36538A (fr) |
| WO (1) | WO2016123019A1 (fr) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| JP2014527799A (ja) | 2011-08-26 | 2014-10-23 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| AR102198A1 (es) | 2014-10-09 | 2017-02-08 | Regeneron Pharma | Proceso para reducir partículas subvisibles en una formulación farmacéutica |
| TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| TWI870789B (zh) | 2015-08-04 | 2025-01-21 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| US11197925B2 (en) | 2016-02-19 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Influenza B virus replication for vaccine development |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| US20200148750A1 (en) | 2016-07-21 | 2020-05-14 | Emory University | Ebola Virus Antibodies and Binding Agents Derived Therefrom |
| US11020686B2 (en) | 2016-08-16 | 2021-06-01 | Regeneron Pharmaceuticals, Inc. | Methods for quantitating individual antibodies from a mixture |
| EP3504328A1 (fr) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Modification de protéines de cellules hôtes |
| JP7102401B2 (ja) | 2016-10-25 | 2022-07-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | クロマトグラフィーデータ解析のための方法およびシステム |
| CN113512111B (zh) * | 2017-03-10 | 2023-08-15 | 北京天广实生物技术股份有限公司 | 抗埃博拉病毒单克隆抗体、其制备方法及用途 |
| BR112020000127A2 (pt) | 2017-07-06 | 2020-07-07 | Regeneron Pharmaceuticals, Inc. | método para selecionar um hidrolisado de soja, e, glicoproteína |
| US12162925B2 (en) * | 2017-09-15 | 2024-12-10 | The Wistar Institute Of Anatomy And Biology | DNA-encoded monoclonal antibodies targeting the Ebolavirus glycoprotein |
| CA3073935A1 (fr) | 2017-09-19 | 2019-03-28 | Regeneron Pharmaceuticals, Inc. | Procedes de reduction de la formation de particules et compositions formees par ceux-ci |
| WO2019084310A1 (fr) | 2017-10-25 | 2019-05-02 | Yoshihiro Kawaoka | Virus de la grippe recombinants à ha stabilisé pour la réplication dans des oeufs |
| MX2020006639A (es) | 2017-12-22 | 2020-09-14 | Regeneron Pharma | Sistema y metodo para caracterizar las impurezas de un producto farmaceutico. |
| RU2686630C1 (ru) * | 2017-12-22 | 2019-04-29 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Штаммы гибридных клеток животных Mus. Musculus - продуценты моноклональных антител к белку GP вируса Эбола (subtype Zaire) и моноклональные антитела к белку GP вируса Эбола (subtype Zaire) |
| EP3724223A1 (fr) | 2018-01-02 | 2020-10-21 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anticorps neutralisants dirigés contre la glycoprotéine du virus ebola et leur utilisation |
| BR112020013336A2 (pt) | 2018-01-31 | 2020-12-01 | Regeneron Pharmaceuticals, Inc. | produto farmacêutico proteico, métodos para caracterizar as impurezas do produto farmacêutico proteico de alto peso molecular intermediário, para produção de um anticorpo, e para caracterizar as impurezas de fármaco com variação de carga, anticorpo, e, sistema para caracterizar impurezas de fármaco de alto peso molecular intermediário. |
| WO2019152607A1 (fr) * | 2018-01-31 | 2019-08-08 | The Wistar Institute Of Anatomy And Biology | Constructions d'anticorps d'acide nucléique destinées à être utilisées contre le virus ebola |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| WO2019168774A1 (fr) | 2018-02-28 | 2019-09-06 | Regeneron Pharmaceuticals, Inc. | Systèmes et procédés d'identification de contaminants viraux |
| CN108373500A (zh) * | 2018-03-12 | 2018-08-07 | 中国科学院微生物研究所 | 一种热稳定性埃博拉治疗性抗体的制备及应用 |
| HUE065344T2 (hu) | 2018-03-19 | 2024-05-28 | Regeneron Pharma | Mikrochip kapilláris elektroforézis assay-k és reagensek |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| MA52175A (fr) * | 2018-03-26 | 2021-02-17 | Regeneron Pharma | Anticorps anti-pfrh5 et leurs fragments de liaison à l'antigène |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| TWI853823B (zh) | 2018-07-02 | 2024-09-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
| WO2020014443A1 (fr) * | 2018-07-12 | 2020-01-16 | Vanderbilt University | Anticorps humains neutralisant le virus ebola pandémique et leurs procédés d'utilisation |
| US12343390B2 (en) | 2018-08-07 | 2025-07-01 | Wisconsin Alumni Research Foundation (Warf) | Recombinant biologically contained filovirus vaccine |
| JP7655849B2 (ja) | 2018-08-20 | 2025-04-02 | ウィスコンシン アルムニ リサーチ ファンデイション | ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター |
| CN119264211A (zh) | 2018-08-27 | 2025-01-07 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| JP7511542B2 (ja) | 2018-08-30 | 2024-07-05 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | タンパク質複合体を特徴づけるための方法 |
| CN111138527B (zh) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 抗埃博拉病毒糖蛋白gp1亚基的单克隆抗体4f1及应用 |
| CN111138528B (zh) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 特异性结合于埃博拉病毒糖蛋白聚糖帽的单克隆抗体5a8 |
| CN111138531B (zh) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 特异结合于ebov的gp1亚基的单克隆抗体8f9及应用 |
| CN111138526B (zh) | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 一种抗埃博拉病毒糖蛋白gp2亚基的单克隆抗体2g1及应用 |
| WO2020150491A1 (fr) | 2019-01-16 | 2020-07-23 | Regeneron Pharmaceuticals, Inc. | Méthodes de caractérisation de liaisons disulfures |
| EP3921413A1 (fr) | 2019-02-08 | 2021-12-15 | Wisconsin Alumni Research Foundation (WARF) | Lignée cellulaire humanisée |
| EA202192422A1 (ru) | 2019-03-05 | 2021-12-09 | Ридженерон Фармасьютикалз, Инк. | Человеческий сывороточный альбумин в составах |
| CN114929269A (zh) | 2019-05-01 | 2022-08-19 | 威斯康星校友研究基金会(Warf) | 用于疫苗开发的改进的流感病毒复制 |
| WO2020231992A1 (fr) | 2019-05-13 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Dosages améliorés de liaison de ligands compétitifs |
| US11807872B2 (en) | 2019-08-27 | 2023-11-07 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| JP6761889B1 (ja) * | 2019-11-11 | 2020-09-30 | 株式会社Ｇｓｐエンタープライズ | 抗ヒトＣｒｉｐｔｏ−１抗体 |
| CA3158119A1 (fr) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Formulations a liberation prolongee utilisant des emulsions non aqueuses |
| GB201917480D0 (en) * | 2019-11-29 | 2020-01-15 | Univ Oxford Innovation Ltd | Antibodies |
| CN115398236B (zh) | 2020-01-21 | 2024-06-11 | 瑞泽恩制药公司 | 用于糖基化的蛋白质的电泳的去糖基化方法 |
| JP7674369B2 (ja) * | 2020-01-24 | 2025-05-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 安定な抗体製剤 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| JP2023511444A (ja) | 2020-01-24 | 2023-03-17 | ウィスコンシン アルムニ リサーチ ファンデイション | 安定化されたｎａを有する組換えインフルエンザウイルス |
| BR112022017048A2 (pt) | 2020-02-26 | 2022-11-16 | Vir Biotechnology Inc | Anticorpos contra sars-cov-2 e métodos para usar os mesmos |
| WO2021195410A1 (fr) | 2020-03-25 | 2021-09-30 | Wisconsin Alumni Research Foundation (Warf) | Virus de la grippe multivalents recombinants |
| CN116390771A (zh) * | 2020-07-13 | 2023-07-04 | 瑞泽恩制药公司 | 与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途 |
| WO2022047108A1 (fr) | 2020-08-31 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Stratégies d'alimentation d'asparagine pour améliorer la performance de culture cellulaire et atténuer des variants de séquence d'asparagine |
| WO2022074630A1 (fr) * | 2020-10-09 | 2022-04-14 | Auxilla Pharmaceuticals And Research Llp | Suspension orale liquide de favipiravir |
| WO2022115588A1 (fr) | 2020-11-25 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Formulations à libération prolongée à l'aide d'une émulsification par membrane non aqueuse |
| KR20230121854A (ko) | 2020-12-17 | 2023-08-21 | 리제너론 파아마슈티컬스, 인크. | 단백질-캡슐화 마이크로겔의 제작 |
| WO2022150809A1 (fr) * | 2021-01-05 | 2022-07-14 | Immunome, Inc. | Cocktail d'anticorps contre la protéine de spicule de sars-cov-2 |
| MX2023008527A (es) | 2021-01-20 | 2023-07-28 | Regeneron Pharma | Metodos para mejorar el valor proteico en cultivo celular. |
| JP2024512299A (ja) | 2021-03-03 | 2024-03-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | タンパク質の粘度を定量及び変更するためのシステム及び方法 |
| BR112023024984A2 (pt) | 2021-06-01 | 2024-02-20 | Regeneron Pharma | Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit |
| US20230077710A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS |
| CA3232463A1 (fr) | 2021-09-20 | 2023-03-23 | Philip Mellors | Procedes de controle de l'heterogeneite d'anticorps |
| CA3230984A1 (fr) | 2021-10-07 | 2023-04-13 | Ross BROWNE | Systemes et methodes de modelisation et de regulation du ph |
| WO2023059803A1 (fr) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Étalonnage et correction de ph-mètre |
| TW202330104A (zh) | 2021-10-26 | 2023-08-01 | 美商再生元醫藥公司 | 用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法 |
| AU2023208050A1 (en) | 2022-01-14 | 2024-07-04 | Regeneron Pharmaceuticals, Inc. | Verrucarin a derivatives and antibody drug conjugates thereof |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| EP4655595A1 (fr) | 2023-01-25 | 2025-12-03 | Regeneron Pharmaceuticals, Inc. | Caractérisation basée sur la spectrométrie de masse d'anticorps co-exprimés in vivo |
| WO2024163708A1 (fr) | 2023-02-01 | 2024-08-08 | Regeneron Pharmaceuticals, Inc. | Fractionnement en continu à flux asymétrique avec spectrométrie de masse pour analyse biomacromoléculaire |
| EP4669963A2 (fr) | 2023-02-22 | 2025-12-31 | Regeneron Pharmaceuticals, Inc. | Paramètres d'adéquation de système et vieillissement de colonne |
| US20240366471A1 (en) | 2023-05-01 | 2024-11-07 | Regeneron Pharmaceuticals, Inc. | Multidose antibody drug products using phenol or benzyl alcohol |
| US20250109905A1 (en) | 2023-09-29 | 2025-04-03 | Regeneron Pharmaceuticals, Inc. | Lyophilization using controlled nucleation |
| US20250129117A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| US20250145662A1 (en) | 2023-11-02 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| WO2025166281A1 (fr) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Plateforme d'analyse par spectrométrie de masse à détection de charge d'aavs |
| WO2025175164A1 (fr) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Procédés de production de substances médicamenteuses formulées concentrées comprenant des protéines, et substance médicamenteuse formulée concentrée fabriquée par les procédés |
| TW202602489A (zh) | 2024-03-15 | 2026-01-16 | 美商再生元醫藥公司 | 作為經穩定的蛋白質調配物之賦形劑的聚山梨醇酯及聚氧乙烯山梨糖醇酐 |
| WO2026025028A1 (fr) | 2024-07-26 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Procédés de fabrication de formulations protéiques à concentration ultra-élevée par lyophilisation |
| CN120943942A (zh) * | 2024-09-12 | 2025-11-14 | 南京诺唯赞生物科技股份有限公司 | 特异性结合hpv的抗体 |
| WO2026060350A1 (fr) | 2024-09-13 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Procédés d'amélioration de la photostabilité et de contrôle de la formation d'espèces hmw dans des formulations biologiques, et formulations biologiques produites par les procédés |
| WO2026076201A2 (fr) | 2024-10-03 | 2026-04-09 | Regeneron Pharmaceuticals, Inc. | Systèmes et procédés de production de protéines thérapeutiques par filtration tangentielle à passage unique pour la concentration en ligne et la réduction volumique de groupes de production |
| WO2026080597A1 (fr) | 2024-10-08 | 2026-04-16 | Regeneron Pharmaceuticals, Inc. | Administration prolongée de produits biologiques et fabrication non aqueuse de ceux-ci |
| CN119462912B (zh) * | 2025-01-15 | 2025-08-19 | 中国人民解放军军事科学院军事医学研究院 | 抗埃博拉病毒vp40蛋白的纳米抗体及在病毒检测中的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7089600A (en) | 1999-08-30 | 2001-03-26 | U.S. Army Medical Research Institute Of Infectious Diseases | Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6875433B2 (en) | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| WO2009094755A1 (fr) | 2008-02-01 | 2009-08-06 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Anticorps monoclonaux contre les virus d'ebola et de marburg |
| EP3351628B1 (fr) | 2008-10-24 | 2023-07-26 | The Government of The United States of America as represented by The Secretary, Department of Health and Human Services | Espèce de virus ebola humain et compositions et procédés associés |
| US8409838B2 (en) | 2009-06-02 | 2013-04-02 | Regeneron Pharmaceuticals, Inc. | Fucosylation-deficient cells |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| US9097713B2 (en) | 2009-09-02 | 2015-08-04 | The United States Of America As Represented By The Secretary Of The Army On Behalf Of Usamrmc | Monoclonal antibodies against glycoprotein of Ebola sudan boniface virus |
| US9346875B2 (en) | 2013-06-03 | 2016-05-24 | Albert Einstein College Of Medicine, Inc. | Therapy for filovirus infection |
| WO2015127136A2 (fr) | 2014-02-19 | 2015-08-27 | Jody Berry | Anticorps monoclonaux anti-ebola |
| CN103864904B (zh) * | 2014-03-04 | 2016-01-20 | 中国人民解放军军事医学科学院生物工程研究所 | 基于埃博拉病毒包膜蛋白的抗原片段、截短体及应用 |
| US20170158753A1 (en) | 2014-06-25 | 2017-06-08 | Integrated Biotherapeutics, Inc. | Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species |
| US10435461B2 (en) | 2014-08-20 | 2019-10-08 | Albert Einstein College Of Medicine | Therapy for filovirus infection |
| JP2017531642A (ja) | 2014-10-03 | 2017-10-26 | マサチューセッツ インスティテュート オブ テクノロジー | エボラ糖タンパク質に結合する抗体およびその使用 |
| WO2016061504A2 (fr) | 2014-10-17 | 2016-04-21 | The University Of Chicago | Anticorps de recombinaison qui reconnaissent les domaines c-terminal de la nucléoprotéine du virus ebola |
| TWI710573B (zh) * | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
-
2016
- 2016-01-22 TW TW105101967A patent/TWI710573B/zh active
- 2016-01-24 MA MA41421A patent/MA41421B1/fr unknown
- 2016-01-25 EP EP25206939.8A patent/EP4653051A3/fr active Pending
- 2016-01-25 JP JP2017536549A patent/JP6829199B2/ja active Active
- 2016-01-25 SG SG10202007835QA patent/SG10202007835QA/en unknown
- 2016-01-25 PL PL16703030.3T patent/PL3250591T3/pl unknown
- 2016-01-25 KR KR1020177021579A patent/KR102641731B1/ko active Active
- 2016-01-25 LT LTEPPCT/US2016/014720T patent/LT3250591T/lt unknown
- 2016-01-25 DK DK16703030.3T patent/DK3250591T3/da active
- 2016-01-25 PT PT167030303T patent/PT3250591T/pt unknown
- 2016-01-25 ES ES16703030T patent/ES3054263T3/es active Active
- 2016-01-25 SI SI201631929T patent/SI3250591T1/sl unknown
- 2016-01-25 SM SM20250454T patent/SMT202500454T1/it unknown
- 2016-01-25 MY MYPI2021007427A patent/MY196224A/en unknown
- 2016-01-25 MD MDE20170310T patent/MD3250591T2/ro unknown
- 2016-01-25 FI FIEP16703030.3T patent/FI3250591T3/fi active
- 2016-01-25 HR HRP20251642TT patent/HRP20251642T1/hr unknown
- 2016-01-25 MY MYPI2023001378A patent/MY208081A/en unknown
- 2016-01-25 CN CN201680018389.XA patent/CN107667115B/zh active Active
- 2016-01-25 EP EP16703030.3A patent/EP3250591B1/fr active Active
- 2016-01-25 WO PCT/US2016/014720 patent/WO2016123019A1/fr not_active Ceased
- 2016-01-25 SG SG11201705681YA patent/SG11201705681YA/en unknown
- 2016-01-25 MY MYPI2017702504A patent/MY180045A/en unknown
- 2016-01-25 EA EA201791675A patent/EA038993B1/ru unknown
- 2016-01-25 AU AU2016211783A patent/AU2016211783B2/en active Active
- 2016-01-25 MX MX2017009716A patent/MX392533B/es unknown
- 2016-01-25 RS RS20251307A patent/RS67563B1/sr unknown
- 2016-01-25 US US15/005,334 patent/US9771414B2/en active Active
- 2016-01-25 CA CA2974899A patent/CA2974899A1/fr active Pending
- 2016-01-25 PH PH1/2017/501277A patent/PH12017501277B1/en unknown
- 2016-01-25 BR BR112017015845-0A patent/BR112017015845A2/en active Search and Examination
- 2016-01-25 CN CN202110499070.6A patent/CN113354732B/zh active Active
- 2016-01-25 MY MYPI2019007583A patent/MY189452A/en unknown
- 2016-01-26 UY UY0001036538A patent/UY36538A/es active IP Right Grant
-
2017
- 2017-07-09 IL IL253358A patent/IL253358B/en unknown
- 2017-07-26 MX MX2021015687A patent/MX2021015687A/es unknown
- 2017-07-26 CL CL2017001920A patent/CL2017001920A1/es unknown
- 2017-07-27 CO CONC2017/0007619A patent/CO2017007619A2/es unknown
- 2017-08-28 US US15/688,474 patent/US10081670B2/en active Active
-
2018
- 2018-08-22 US US16/108,096 patent/US10501526B2/en active Active
-
2019
- 2019-10-24 US US16/663,261 patent/US10829544B2/en active Active
-
2020
- 2020-02-28 CL CL2020000498A patent/CL2020000498A1/es unknown
- 2020-05-07 JP JP2020081768A patent/JP7672200B2/ja active Active
- 2020-09-30 US US17/039,557 patent/US11530255B2/en active Active
-
2021
- 2021-05-05 AU AU2021202839A patent/AU2021202839A1/en not_active Abandoned
-
2022
- 2022-11-09 US US18/053,927 patent/US12152067B2/en active Active
- 2022-12-26 CL CL2022003763A patent/CL2022003763A1/es unknown
-
2023
- 2023-03-07 JP JP2023034449A patent/JP2023065648A/ja active Pending
-
2025
- 2025-02-10 JP JP2025019929A patent/JP7796918B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY180045A (en) | Human antibodies to ebola virus glycoprotein | |
| PH12018502673A1 (en) | Anti-zika virus antibodies and methods of use | |
| PH12017500949A1 (en) | Human antibodies to influenza hemagglutinin | |
| MX2022005253A (es) | Anticuerpos neutralizantes de poliomavirus. | |
| GEAP202114828A (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| PH12020551051A1 (en) | Human antibodies to influenza hemagglutinin | |
| WO2020106358A8 (fr) | Nouveaux anticorps contre le virus zika et utilisations associées | |
| EA201791525A3 (ru) | Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w | |
| MX2020007050A (es) | Una combinacion de inmunoglobulina plasmatica e inmunoglobulina especifica de antigeno para la modificacion del sistema inmune y el tratamiento o prevencion de enfermedades alergicas. | |
| PH12022550963A1 (en) | Anti-hemagglutinin antibodies and methods of use thereof | |
| HK1240605A1 (zh) | 针对埃博拉病毒糖蛋白的人抗体 | |
| EA202191973A2 (ru) | Человеческие антитела к гликопротеину вируса эбола | |
| WO2017211843A8 (fr) | Anticorps polyclonaux antiviraux contre le virus ebola et leurs utilisations | |
| HK1238655A1 (en) | Human antibodies to influenza hemagglutinin | |
| EA201990300A1 (ru) | Антитела к вирусу зика и способы их применения | |
| AR104480A1 (es) | Anticuerpos humanos contra la glicoproteína del virus del ébola |